TargaZyme

The Next Frontier of Cancer Medicine

TargaZyme

The Next Frontier of Cancer Medicine

Closing in 2 days
Carlsbad, CA
Biotechnology
TargaZyme is pioneering the next frontier of cancer medicine with the development of therapeutics that harnesses the power of a patient’s own immune system without the toxic chemotherapies, radiation, radical surgery or other toxic cancer drugs that make up today’s standard of care. TargaZyme is currently pre-revenue and in the R&D stage with our two breakthrough approaches: TZ101, a Phase-3 ready product, and TZ102, which is currently being prepared for clinical or human-patient trials.

$43,185

raised
55
Investors
$196M
Valuation
$6.62
Price per Share
$595.80
Min. Investment
Common
Shares Offered
Equity
Offering Type
$1.07M
Offering Max
2
Days Left

$43,185

raised
55
Investors
$196M
Valuation
$6.62
Price per Share
$595.80
Min. Investment
Common
Shares Offered
Equity
Offering Type
$1.07M
Offering Max
2
Days Left

Stack Owner's Bonus & Rewards!

Members get an extra 10% shares in addition to rewards below!

Rewards

Get rewarded for investing more into TargaZyme:

$595+
Investment
StartEngine Owner’s Bonus
This offering is eligible for the StartEngine Owner’s 10% Bonus program. For details on this program, please see the Offering Summary section below.
$5,000+
Investment
$5,000+
Invest $5,000+ and receive 5% Bonus Shares
$10,000+
Investment
$10,000+
Invest $10,000+ and receive 10% Bonus Shares

Reasons to Invest

A single dose of our novel patented medicine TZ101 was shown to improve survival of terminally ill cancer patients from 64% post-100 days of transplant to 78% post-100 days of transplant by preventing various diseases such as infections, GvHD, hemorrhaging, and stem cell engraftment failure in a Phase 2 clinical (human) trial at M D Anderson Center in Texas.
TargaZyme has been awarded over 38 worldwide patents, with over 40 patent-pending applications, and multiple orphan drug awards.
We have received $50m+ in funding to date, of which, $40m+ originated from highly prestigious medical awards. The team has worked with leading medical centers including MD Anderson Cancer Center, University of Pennsylvania Medical Center, Yale Medical Center, Harvard University Medical School, and Cleveland Clinic.

Harnessing the power of your immune system to fight cancer

Imagine the next frontier of cancer medicine, where you or your loved ones could potentially be cured by leveraging the power of your own immune system. 


With TargaZyme’s novel, patented medicine, cancer-fighting T-cells can be harnessed to eliminate cancer without the harmful side effects and safety issues of current treatments such as chemo, radiation, and radical surgery, many of which only extend life by a few months.



Our novel drugs are patented worldwide and have been validated by renowned medical minds in leading cancer centers in the US. Most important of all, TargaZyme’s treatments have already shown an extremely exciting improvement in patient survival rates after 100 days.


Cancer care is overdue for new advancements, and we believe TargaZyme will be ready to deliver. By removing the pain for cancer patients and improving their prospects for survival and a healthy life, post-cancer, we have the potential to make an enormous difference. We’re committed to developing breakthrough medicine that we hope will have life-changing effects for cancer patients and their families.


TargaZyme is currently pre-revenue and in the R&D stage with our two breakthrough approaches: TZ101, a Phase-3 ready product, and TZ102, which is currently being prepared for clinical or human-patient trials.

The Problem


Current cancer treatments threaten a patient's long-term quality of life

Anyone who’s experienced cancer—whether first-hand or through a loved one—knows that it’s a harrowing, traumatic experience. While modern medicine has brought incredible advancements, we believe the current standard of care for cancer patients remains inadequate


Current cancer treatments are focused on highly toxic chemotherapy, radiation, radical surgery, or drugs that may extend life by only a few months, often accompanied by major side effects. Chemotherapy is a poison with toxic, life-long side effects that create a long-term impact on a patient's quality of life. 


But what if rather than extend a patient’s life by a few months, we could provide a solution that eliminates the disease entirely without the toxic treatments?


Pictured above, from left-to-right: 1.) Cancer cells being attacked by T-cells, 2.) A typical catheter setup that allows for the delivery of medicine and nutrition IV, 3.) Example of cell division (also known as mitosis).

The Solution


Supplanting harmful treatments with cancer immunotherapy

TargaZyme is at the forefront of a breakthrough approach called cancer immunotherapy, which seeks to harness the power of a patient’s own immune system rather than relying on harmful chemotherapy or surgery. Our goal is to cure the patient, not simply treat them, by supercharging the immune system to eliminate the cancer. 


Patients with solid tumors could potentially be cured successfully with the patients’ own cancer-fighting T Cells, augmented by our breakthrough drugs, TZ101 and TZ102. This heralds the incredible potential to supplant the use of various toxic cancer therapies, radiation, and radical surgery that make up the current standard of care.



TargaZyme is researching, developing, and working to commercialize enzymes that enhance immune response, whether autologous (from a patient’s own cells) or allogeneic (derived cells).


These enzymes catalyze the body's immune response by directing the cells directly to the disease site. TZ101 and TZ102, delivered to a patient through IV Infusion, enhance the natural mechanism by which circulating cells reach the diseased tissues.


Additionally, they improve the extent and rate of stem cell engraftment while reducing the incidence of life-threatening infections and GvHD.  Finally, they increase residence time of anti-inflammatory cells in sites of inflammation, thus significantly reducing patient infection rates compared to historic controls.


In our Phase 2 clinical trials at MD Anderson Cancer Center, a single dose of TZ 101 was shown to improve survival of terminally ill cancer patients from 64% post-100 days of transplant to 78% post-100 days of transplant by preventing various diseases such as infections, GvHD, hemorrhaging, and stem cell engraftment failure.


Equally exciting is that TargaZyme’s enzymes have broad potential utility across all therapeutic categories beyond oncology. We hope to expand the biotechnology to all applicable instances where a patient's body can fight disease with immune responses.

The Market


An early-stage entry point into multiple billion dollar markets

All of TargaZyme’s markets are large, well-defined treatment categories with annual spends in the billions of dollars in the US alone. The cell therapy market was valued at $9.5B in 2021, while the oncology market is projected to reach over $581B by 2030 (sourcesource).


The COVID-19 pandemic has further emphasized worldwide health challenges, prompting a major shift in healthcare investments and subsequent growth for companies like TargaZyme.


(source, source)


TargaZyme’s closest competitors use methods that are much more time consuming and resource intensive. We have a therapeutic with a production similar to Genzyme (acquired by Sanofi for $20B in 2011; source) in the sense that we are restoring or replacing a recombinant enzyme. However, what makes us unique is our ability to make cures safe, tractable, and expandable across multiple cellular therapeutic types and a variety of diseases.


Historically therapeutics have treated disease, but not provided cures. As our cellular therapy is working to offer patients the possibility of a healthy post-cancer life, there’s understandably excitement about it.

Our Traction


Over 35 patents, $40M in medical awards, and a clear FDA pathway

TargaZyme has received over $40M in prestigious medical awards and has collaborated with great medical minds at leading cancer centers such as MD Anderson Cancer Center, University of Pennsylvania Medical Center, Yale Medical Center, Harvard University Medical School, Duke Medical Center, Oklahoma Medical Research Foundation, and Cleveland Clinic. Our team is extremely proud to have won more competitive medical prizes and published more peer-reviewed medical papers than many of today's publicly listed biotech companies. 



We’ve secured over 35 worldwide patents, with over 40 patent-pending applications. As such, TargaZyme has the leading fucosylating-enzyme intellectual-property position, a statement which has been validated by two important third parties of note. One is an independent valuation firm involved in our cross-license with Kyowa Hakko Kirin. The other is multinational biopharmaceutical company, Kyowa Hakko Kirin, itself. Their conclusion was TargaZyme has the pre-eminent position in the space, thus driving their decision to cross-license with TargaZyme.


TargaZyme has been awarded a Phase 3 Special Protocol Assessment by the FDA and has received multiple FDA orphan-drug designations which extend the commercial value of TargaZyme’s Therapies. We’re now in Phase 2 clinical trials, and have a clear FDA pathway towards first approval—which means we’re well on our way to commercializing TargaZyme products.


Funds raised during this campaign will be used towards manufacturing, validating clinical trials towards FDA product approval, worldwide patents, and working capital to support continued momentum towards these key milestones.

Why Invest


A biotech investment towards a life-saving mission

Our conversations with potential investors have proven that biotech is an attractive equity asset class, but too many early-stage companies, including any public companies, are much too far from commercialization to offer the right balance of risk and return. TargaZyme has specifically chosen StartEngine to offer everyday investors the opportunity to join us on the ground floor with an advanced, clinical-stage lead candidate. With early data showing that our products are safe and efficacious in patients, plus support from the FDA that we’re addressing major, unmet medical needs, we believe TargaZyme is the rare, mission-oriented investment opportunity for which many investors have been looking.


By 2030, we plan to be generating multiple revenue streams with major product partnering and licensing, enabling the delivery of cancer cures and further development of multiple additional cures in SCT and autoimmune disease. By 2040, we aim to be one of the leading names in biotech, with a leadership position in cell therapy.


Too many people suffer through cancer and its losses. TargaZyme is ready to create a major legacy as we work towards a cancer-free world.

Remove
Browse
Drop image
(or click)

Loading image

In the Press

Clinical Cancer Research

Fucosylation Enhances the Efficacy of Adoptively Transferred Antigen-Specific Cytotoxic T Lymphocytes

American Society of Hematology ("ASH") Blood

Ex vivo fucosylation of third-party human regulatory T cells enhances anti–graft-versus-host disease potency in vivo

Journal of Biological Chemistry ("JBC")

Glycoengineering of chimeric antigen receptor (CAR) T-cells to enforce E-selectin binding

Offering Summary


Company

:

TargaZyme, Inc

Corporate Address

:

2100 Palomar Airport Road, Suite 214-219, Carlsbad, CA 92011

Offering Minimum

:

$9,996.20

Offering Maximum

:

$1,069,997.22

Minimum Investment Amount

(per investor)

:

$595.80











Terms


Offering Type

:

Equity

Security Name

:

Common Stock

Minimum Number of Shares Offered

:

1,510

Maximum Number of Shares Offered

:

161,631

Price per Share

:

$6.62

Pre-Money Valuation

:

$196,273,334.80











*Maximum Number of Shares Offered subject to adjustment for bonus shares. See Bonus info below.

Investment Incentives and Bonuses*

Time-Based:

Friends and Family Early Birds
Invest within the first week and receive 10% Bonus Shares

Super Early Bird Bonus
Invest within the first two weeks and receive 8% Bonus Shares

Early Bird Bonus
Invest within the first three weeks and receive 5% Bonus Shares

Amount-Based:

$5,000+
Invest $5,000+ and receive 5% Bonus Shares

$10,000+
Invest $10,000+ and receive 10% Bonus Shares

*All perks occur when the offering is completed.

The 10% StartEngine Owners' Bonus

TargaZyme will offer 10% additional bonus shares for all investments that are committed by investors that are eligible for the StartEngine Crowdfunding Inc. OWNer's bonus.

This means eligible StartEngine shareholders will receive a 10% bonus for any shares they purchase in this offering. For example, if you buy 100 shares of Common Stock at $6.62 / share, you will receive 110 shares of Common Stock, meaning you'll own 110 shares for $662. Fractional shares will not be distributed and share bonuses will be determined by rounding down to the nearest whole share.

This 10% Bonus is only valid during the investors eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are canceled or fail.

Investors will receive the highest single bonus they are eligible for among the bonuses based on the amount invested and time of offering elapsed (if any).

Irregular Use of Proceeds

The Company might incur Irregular Use of Proceeds that may include but are not limited to the following over $10,000: Vendor payments. Salary payments made to one’s self, a friend or relative. Inter company debt or back payments.

Show More
Most recent fiscal year-end:
Prior fiscal year-end:
Total Assets
$3,174,319.00 USD
$3,455,588.00 USD
Cash And Cash Equivalents
$111,900.00 USD
$19,562.00 USD
Accounts Receivable
$0.00 USD
$0.00 USD
Short Term Debt
$474,301.00 USD
$270,050.00 USD
Long Term Debt
$7,490,811.00 USD
$7,269,726.00 USD
Revenues And Sales
$0.00 USD
$0.00 USD
Costs Of Goods Sold
$0.00 USD
$0.00 USD
Taxes Paid
$0.00 USD
$0.00 USD
Net Income
-$2,416,916.00 USD
-$2,483,254.00 USD

Risks

A crowdfunding investment involves risk. You should not invest any funds in this offering unless you can afford to lose your entire investment. In making an investment decision, investors must rely on their own examination of the issuer and the terms of the offering, including the merits and risks involved. These securities have not been recommended or approved by any federal or state securities commission or regulatory authority. Furthermore, these authorities have not passed upon the accuracy or adequacy of this document. The U.S. Securities and Exchange Commission does not pass upon the merits of any securities offered or the terms of the offering, nor does it pass upon the accuracy or completeness of any offering document or literature. These securities are offered under an exemption from registration; however, the U.S. Securities and Exchange Commission has not made an independent determination that these securities are exempt from registration.


Updates

Notice of Material Change in Offering

about 2 months ago

[The following is an automated notice from the StartEngine team].

Hello! Recently, a change was made to the TargaZyme offering. Here's an excerpt describing the specifics of the change:


Issuer is increasing minimum investment amount and removing a D&O.


When live offerings undergo changes like these on StartEngine, the SEC requires that certain investments be reconfirmed. If your investment requires reconfirmation, you will be contacted by StartEngine via email with further instructions.

Show More Updates End of Updates

Comments ({{profileCtrl.startup.comments_count}} total)

{{profileCtrl.newComment.body.length}}/2500
Please sign in to post a comment.
Please use Updates for communications.
{{ profileCtrl.commentsLoading ? 'Loading...' : 'Show More Comments' }}